S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(-1.22%) $77.99
Gas
(5.65%) $2.15
Gold
(0.02%) $2 310.10
Silver
(-0.16%) $26.79
Platinum
(0.37%) $966.20
USD/EUR
(-0.35%) $0.929
USD/NOK
(-1.07%) $10.87
USD/GBP
(-0.11%) $0.797
USD/RUB
(0.35%) $91.45

Aktualne aktualizacje dla Alterity Therapeutics Ltd [ATH.AX]

Giełda: ASX Branża: Pharmaceuticals, Biotechnology & Life Sciences
Ostatnio aktualizowano3 geg. 2024 @ 09:10

-16.67% $ 0.00500

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 09:10):
Profile picture for Alterity Therapeutics Ltd

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia...

Stats
Dzisiejszy wolumen 91.11M
Średni wolumen 12.14M
Kapitalizacja rynkowa 31.47M
EPS $0 ( 2024-02-29 )
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.500
ATR14 $0 (0.00%)

Alterity Therapeutics Ltd Korelacja

10 Najbardziej pozytywne korelacje
10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alterity Therapeutics Ltd Finanse

Annual 2023
Przychody: $3.92M
Zysk brutto: $3.63M (92.72 %)
EPS: $-0.00570
FY 2023
Przychody: $3.92M
Zysk brutto: $3.63M (92.72 %)
EPS: $-0.00570
FY 2023
Przychody: $0
Zysk brutto: $0 (0.00 %)
EPS: $0
FY 2022
Przychody: $5.12M
Zysk brutto: $4.76M (92.88 %)
EPS: $-0.00530

Financial Reports:

No articles found.

Alterity Therapeutics Ltd

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej